Tamsulosin – a new insight on a well-known medicine Review article
Article Sidebar
Published:
Jun 30, 2020
Keywords:
tamsulosin, α1-adrenergic receptor antagonists, OCAS, treatment, benign prostatic hyperplasia, hypertension
Main Article Content
Abstract
After subsequent cardiac societies’ guidelines definitely declassified the group of α-blockers as drugs recommended for I line treatment, a successful therapy for patients with prostatic hyperplasia appeared to be a challenge. At that time, tamsulosin, due to its unique and highly selective mechanism of action against α1-adrenergic receptors (found in prostate), proved to be a promising direction in terms of benign prostatic hyperplasia treatment. Clinical research results, together with the progress of pharmaceutical technology, allow to establish a promising, highly effective and, above all, safe therapy for patients diagnosed with prostatic hyperplasia.
Article Details
How to Cite
Jarosz-Popek , J., Czajka , P., & Postuła , M. (2020). Tamsulosin – a new insight on a well-known medicine. Medycyna Faktow (J EBM), 13(2(47), 188-191. https://doi.org/10.24292/01.MF.0220.7
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Moser M. Myths, misconceptions and heroics. The story of the treatment of hypertension form the 19309. Le Jacq Communications. Inc., Greenwich, Connecticut 1997: 1-68.
2. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136: 1-4.
3. Insel PA. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med. 1996; 344: 580-5.
4. Veelken R, Schmieder RE. Overview of a1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens. 1996; 9: 139S-49S.
5. Ejchman W. BPH-fitoterapia. Zalety i działania niepożądane. Prz Urol. 2004; 5(1): 26-7.
6. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168: 7-12.
7. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Urticae radix. 2nd ed. Nortfolk. 2003: 528-35.
8. Weiss RF, Fintelmann V. Herbal Medicine. 2nd ed. Stuttgart – New York 2000: 236-9.
9. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan Jr ED et al (ed). Campbell’s urology. 8th ed. Saunders, Filadelfia 2002: 1297-330.
10. Zdrojewski T, Bandosz P, Szpakowski P et al. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL PLUS. In: Więcek A, Kokot F (ed). Postępy w nefrologii i nadciśnieniu tętniczym. Vol. 2. Medycyna Praktyczna, Kraków 2002: 11-5.
11. Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B et al. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol Pol. 2005; 63: 6(S4).
12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-75.
13. Farmer R, Hutchison A, Chapple C. Comparison of the treatment regimens of new and existing LUTS/BPH patients in 6 European countries. Eur Urol Suppl. 2004; 3(2): 60 [Abstract 230].
14. Abrams P, Schulman CC. Vaage S, for the European Tamsulosin Study Group. Tamsulosin, a selective α1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995; 76: 325-36.
15. Lepor H; for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia. Placebo-controlled, double- blind extension of phase III trial. Urology. 1998; 51: 901-6.
16. Chapple CR, Wyndaele JJ, Nordling J et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996; 29: 155-67.
17. Michel MC, Grübbel B, Taguchi K et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha-1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996; 16: 21-8.
18. Schwinn DA, Michelotti GA. α1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1D subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000; 85(suppl 2): 6-11.
19. Romic I, Kiss T, Kisbenedek L et al. Tamsulosin drug ratio in prostate versus free fraction in plasma supports pharmacokinetic (PK) contribution to its uroselectivity. J Urol. 2003; 169(4 suppl): 288 [Abstract 1118].
20. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin. An update of its role in the management of lower urinary tract symptoms. Drugs. 2002; 62: 135-67.
21. Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl. 2005; 4(2): 9-14.
22. Michel MC, Korstanje C, Krauwinkel W et al. Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. Eur Urol Suppl. 2005; 4(2): 53-60.
2. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136: 1-4.
3. Insel PA. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med. 1996; 344: 580-5.
4. Veelken R, Schmieder RE. Overview of a1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens. 1996; 9: 139S-49S.
5. Ejchman W. BPH-fitoterapia. Zalety i działania niepożądane. Prz Urol. 2004; 5(1): 26-7.
6. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168: 7-12.
7. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Urticae radix. 2nd ed. Nortfolk. 2003: 528-35.
8. Weiss RF, Fintelmann V. Herbal Medicine. 2nd ed. Stuttgart – New York 2000: 236-9.
9. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan Jr ED et al (ed). Campbell’s urology. 8th ed. Saunders, Filadelfia 2002: 1297-330.
10. Zdrojewski T, Bandosz P, Szpakowski P et al. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL PLUS. In: Więcek A, Kokot F (ed). Postępy w nefrologii i nadciśnieniu tętniczym. Vol. 2. Medycyna Praktyczna, Kraków 2002: 11-5.
11. Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B et al. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol Pol. 2005; 63: 6(S4).
12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-75.
13. Farmer R, Hutchison A, Chapple C. Comparison of the treatment regimens of new and existing LUTS/BPH patients in 6 European countries. Eur Urol Suppl. 2004; 3(2): 60 [Abstract 230].
14. Abrams P, Schulman CC. Vaage S, for the European Tamsulosin Study Group. Tamsulosin, a selective α1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995; 76: 325-36.
15. Lepor H; for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia. Placebo-controlled, double- blind extension of phase III trial. Urology. 1998; 51: 901-6.
16. Chapple CR, Wyndaele JJ, Nordling J et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996; 29: 155-67.
17. Michel MC, Grübbel B, Taguchi K et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha-1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996; 16: 21-8.
18. Schwinn DA, Michelotti GA. α1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1D subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000; 85(suppl 2): 6-11.
19. Romic I, Kiss T, Kisbenedek L et al. Tamsulosin drug ratio in prostate versus free fraction in plasma supports pharmacokinetic (PK) contribution to its uroselectivity. J Urol. 2003; 169(4 suppl): 288 [Abstract 1118].
20. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin. An update of its role in the management of lower urinary tract symptoms. Drugs. 2002; 62: 135-67.
21. Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl. 2005; 4(2): 9-14.
22. Michel MC, Korstanje C, Krauwinkel W et al. Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. Eur Urol Suppl. 2005; 4(2): 53-60.